
|Videos|June 14, 2017
Promising Results for Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Pancreatic Cancer
Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses results of the CanStem111P trial, a phase III study of napabucasin plus nab-paclitaxel with gemcitabine in adult patients with metastatic pancreatic adenocarcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dual BCMA/CD19 CAR T, AZD0120, Yields 96% ORR in Myeloma; Fast Turnaround
2
Linvoseltamab Monotherapy Effective in Newly Diagnosed Multiple Myeloma
3
NCCN Guidelines in nccRCC Weigh New Data for Combinations
4
Subcutaneous Cevostamab Shows Early Promise in R/R Myeloma
5









































